Stock 603168 ZHEJIANG SHAPUAISI PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.

Equities

603168

CNE100001TG0

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
8.7 CNY +1.99% Intraday chart for Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. +1.87% -35.12%
Apr. 19 Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 17 Shapuaisi Pharma Gets China's Nod to Market Sodium Hyaluronate Eye Drops MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,210 2,800 2,529 3,058 3,397 5,085
Enterprise Value (EV) 1 1,615 2,118 2,072 2,852 2,883 4,891
P/E ratio -17.5 x 434 x -14 x 86.2 x 65.7 x 192 x
Yield - 0.13% - - 0.41% -
Capitalization / Revenue 3.64 x 5.43 x 7.06 x 4.88 x 6.18 x 7.88 x
EV / Revenue 2.66 x 4.1 x 5.78 x 4.55 x 5.25 x 7.58 x
EV / EBITDA 19.7 x 60.5 x -44.4 x 24.7 x 29.7 x 58.1 x
EV / FCF 42 x 88.5 x 6.87 x -8.41 x 34 x -61.4 x
FCF Yield 2.38% 1.13% 14.5% -11.9% 2.94% -1.63%
Price to Book 1.49 x 1.88 x 1.94 x 2.26 x 1.99 x 2.47 x
Nbr of stocks (in thousands) 322,592 322,592 322,592 322,592 372,514 379,162
Reference price 2 6.850 8.680 7.840 9.480 9.120 13.41
Announcement Date 4/26/19 4/24/20 4/20/21 3/28/22 4/28/23 4/19/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 607.4 516 358.2 627.1 549.5 645
EBITDA 1 82.07 34.99 -46.7 115.4 97.06 84.2
EBIT 1 30.66 -19.81 -110.5 59.93 39.62 19.7
Operating Margin 5.05% -3.84% -30.84% 9.56% 7.21% 3.05%
Earnings before Tax (EBT) 1 -111.5 16.78 -176.5 63.64 55.2 33.08
Net income 1 -126.5 7.857 -179.4 35.66 45.94 25.41
Net margin -20.82% 1.52% -50.07% 5.69% 8.36% 3.94%
EPS 2 -0.3921 0.0200 -0.5600 0.1100 0.1388 0.0700
Free Cash Flow 1 38.45 23.92 301.5 -339 84.68 -79.64
FCF margin 6.33% 4.64% 84.16% -54.06% 15.41% -12.35%
FCF Conversion (EBITDA) 46.85% 68.36% - - 87.24% -
FCF Conversion (Net income) - 304.4% - - 184.34% -
Dividend per Share - 0.0110 - - 0.0370 -
Announcement Date 4/26/19 4/24/20 4/20/21 3/28/22 4/28/23 4/19/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 595 682 457 206 515 194
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 38.5 23.9 301 -339 84.7 -79.6
ROE (net income / shareholders' equity) -8.06% 0.53% -12.8% 3.79% 2.99% 1.46%
ROA (Net income/ Total Assets) 1.09% -0.76% -4.23% 2.3% 1.4% 0.6%
Assets 1 -11,612 -1,028 4,237 1,551 3,286 4,259
Book Value Per Share 2 4.590 4.620 4.050 4.190 4.580 5.430
Cash Flow per Share 2 0.4500 0.6900 0.3300 0.4300 1.410 1.120
Capex 1 58.4 20.3 17.2 153 149 220
Capex / Sales 9.61% 3.94% 4.8% 24.47% 27.06% 34.08%
Announcement Date 4/26/19 4/24/20 4/20/21 3/28/22 4/28/23 4/19/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG SHAPUAISI PHARMACEUTICAL CO.,LTD. Stock Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.
-35.12% 455M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603168 Stock
  4. Financials Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.